QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element
Biosciences, Inc. today announced a strategic partnership to offer
comprehensive next-generation sequencing (NGS) workflows for the
Element AVITI™ System, an innovative sequencing platform.
Element’s AVITI System is a versatile benchtop
sequencer offering a combination of performance, cost, and
flexibility for a wide range of NGS applications. For customers
using the AVITI System, QIAGEN provides Sample to Insight NGS
workflows with validated QIAseq panels and integrated bioinformatic
solutions, including CLC LightSpeed and QCI Interpret software.
“The collaboration between QIAGEN and Element
Biosciences delivers unprecedented insights across various genomic
applications to our customers worldwide. Researchers are
increasingly searching for complete solutions and workflows from
sample to insight, and we are committed to advancing the field
together by providing innovative technology and applications that
help researchers accelerate discovery,” said Nitin Sood, Senior
Vice President, Head of Life Sciences Business Area at QIAGEN.
Yaron Hakak, Ph.D., Senior Vice President of
Corporate and Business Development at Element Biosciences, added:
“Element and QIAGEN share the goals of offering flexible,
cost-effective, and high-performance solutions to our customers.
Jointly promoting the combined workflow will help us serve an
expanded customer base with the backing of a global genomic
powerhouse like QIAGEN.”
QIAGEN’s platform-agnostic QIAseq panels enable
efficient and accurate NGS library preparation. The QIAseq miRNA
Library Kit, the QIAseq xHYB Actionable Exome Panel, and the QIAseq
Targeted DNA Pro Panel have been validated on the AVITI sequencer
with robust performance, high specificity, and coverage uniformity,
as well as consistent variant detection.
LightSpeed, a new module for QIAGEN CLC Genomics
Workbench Premium, enables AVITI System users to perform
cost-effective whole genome sequencing (WGS) secondary analysis
with exceptional runtimes. QCI Interpret, a fully customizable
software solution, facilitates NGS variant interpretation and
reporting for oncology and hereditary applications, with over 3
million reports issued.
“There is a huge potential for NGS to deliver on
the vision of precision medicine. One of the greatest barriers to
ubiquitous adoption and use is the efficient downstream analysis
and interpretation of processed samples,” said Dr. Jonathan
Sheldon, Senior Vice President of QIAGEN Digital Insights. “We are
pleased to partner with Element Biosciences to deliver joint
solutions that enable customers to rapidly adopt, automate, and
scale their NGS needs with higher cost efficiencies and faster
turnaround times.”
More information on the NGS workflow for the AVITI system can be
found here:
https://digitalinsights.qiagen.com/element-aviti-workflows/
Both partners will present data at the American
Society of Human Genetics (ASHG) annual meeting in Washington, DC.
QIAGEN is also collaborating closely with other leading sequencing
platform providers and will offer at ASHG a preview of data
generated with several QIAseq kits on different sequencing
platforms, demonstrating excellent performance and
compatibility.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
September 30, 2023, QIAGEN employed more than 6,000 people in
over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
About Element Biosciences, Inc.
Element Biosciences is a multi-disciplinary life
science company currently focused on developing disruptive DNA
sequencing technology for research and diagnostic markets. Through
innovating every fundamental element of a sequencing system,
Element empowers customers with affordable, high-quality data and
an improved user experience, which in turn will accelerate
scientific discoveries and broaden the use of genomic medicine. To
learn more about Element, please visit
www.elementbiosciences.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Qiagen NV (NYSE:QGEN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024